This week’s China biopharma roundup from PharmaBoardroom content partner Selesta covers Legend Biotech’s planned secondary listing, Betta’s Hong Kong IPO move, iRegene’s USD 40mn raise after FDA Fast Track for its Parkinson’s cell therapy, and Rapafusyn’s USD 44mn Series A for molecular glues. On the clinical front, Junshi posts positive psoriasis Phase III data, Henlius enters the US with its denosumab biosimilar, Yangtze and Daewoong gain China approval for fexuprazan, BioMarin files vosoritide for achondroplasia, and Biokin reports 100% ORR in an EGFR NSCLC combo trial.
